Study study type PathologyT1T0Patientssample sizesROB Results

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
atezolizumab plus bevacizumab
IMbrave-150, 2020
  NCT03434379
RCTmHCC - 1st line (L1)atezolizumab-bevacizumabsorafenibpatients with unresectable hepatocellular carcinoma who had not previously received systemic treatment336 / 165some concern
conclusif
  • demonstrated 42 % decrease in deaths (OS) (PE)
  • demonstrated 41 % decrease in progression or deaths (PFS) (PE)
  • demonstrated 1.8-fold increase in objective responses (ORR) (PE)
atezolizumab plus cabozantinib
COSMIC-312, 2023
  NCT03755791
RCTmHCC - 1st line (L1)cabozantinib plus atezolizumabsorafenibSubjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy432 / 217NA
trade-off
  • inconclusive 2 % decrease in deaths (OS) (PE)
  • demonstrated 37 % decrease in progression or deaths (PFS) (PE)